Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA

Study expands immunology portfolio into autoimmune cytopenias, evaluating a short-duration subcutaneous regimen designed to deplete antibody-producing plasma cells

CAMBRIDGE, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration and Australian Therapeutic Goods Administration have granted clearance to initiate its global Phase 1b/2a clinical trial in adults with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of subcutaneously administered velinotamig, a BCMAxCD3 T cell engager.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.